Acumen Pharmaceuticals, Inc. (ABOS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$52.0M
Cash & Equivalents
$24.1M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$190M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06335173 | A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITU... | PHASE2 | Active Not Recruiting | 542 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-16 | 8-K | Acumen Pharmaceuticals, Inc. (ABOS) (CIK 0001576885) - EX-99.1 | EDGAR |